Gene silencing of human c-myc oncogene by poly-DNP-RNA

Overexpression of the c-myc proto-oncogene has been implicated in the onset and progression of a wide range of cancers; in restenosis following arterial injury or intervention; and in the loss and dysfunction of insulin-producing ??cells in diabetes. UB researchers have synthesized a new compound, DNP002, that triggers cleavage of c-myc mRNA, thereby leading to growth inhibition and apoptosis of cells which overexpress the c-myc gene. Compared to other antisense compounds that have been develo ped to inhibit c-myc gene expression, DNP002 is more potent by at least 2 orders of magnitude. Other advantageous features of the DNP-RNA technology include easier delivery, stability in the presence of RNases, and stereochemical homogeneity, all of which should be valuable for future therapeutic applications.

Categories: Therapeutic and Vaccines, Genomics

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent